Evidence map›Paper›PMID 35894142›Full record

ArticleMolecular medicine reports2022

Decreased RNA‑binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B‑cell lymphoma cells by regulating the p53 signaling pathway.

Yuying Cui, Yu Wen, Chao Lv, Dongmei Zhao, Yu Yang, Hongbin Qiu, Chennan Wang

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. IMPlications of IMP2 in RNA Biology and Disease.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yuying CuiSchool of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Yu WenSchool of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Chao LvSchool of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Dongmei ZhaoSchool of Clinical Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Yu YangSchool of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Hongbin QiuSchool of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Chennan WangSchool of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154007, P.R. China.
Jiamusi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B‑cell lymphoma (DLBCL) remains difficult to treat clinically due to its highly aggressive characteristics. Insulin‑like growth factor 2 mRNA‑binding protein 2 (IGF2BP2) and 5'‑nucleotidase domain‑containing 2 (NT5DC2) have been suggested as potential regulators in numerous types of cancer. The present study aimed to determine whether downregulation of IGF2BP2 and NT5DC2 suppresses cell proliferation, and induces cell cycle arrest and apoptosis in DLBCL cells by regulating the p53 signaling pathway. The expression levels of IGF2BP2 and NT5DC2 in DLBCL cells were determined by reverse transcription‑quantitative PCR (RT‑qPCR) and western blot analysis. Transfection of cells with IGF2BP2 overexpressing plasmids and NT5DC2 interference plasmids was performed, and the efficacy of transfection was confirmed by RT‑qPCR and western blot analysis. The viability, proliferation, cell cycle progression and apoptosis of DLBCL cells were analyzed by Cell Counting Kit‑8 assay, 5‑bromo‑2‑deoxyuridine staining and flow cytometry. RNA pull‑down and immunoprecipitation assays were used to verify the binding of IGF2BP2 and NT5DC2. The expression levels of apoptosis, cell cycle and p53 pathway‑associated proteins were determined by western blotting. The results revealed that NT5DC2 expression was increased in DLBCL cell lines and was the highest in OCI‑Ly7 cells. IGF2BP2 expression was also increased in OCI‑Ly7 cells and IGF2BP2 bound to NT5DC2. Knockdown of NT5DC2 suppressed cell viability and proliferation, induced cell cycle arrest and promoted apoptosis in DLBCL cells, which was reversed by upregulation of IGF2BP2. In addition, knockdown of NT5DC2 increased the expression of p53 and p21, but suppressed the expression of proliferating cell nuclear antigen, CDK4 and cyclin D1; these effects were reversed by upregulation of IGF2BP2. In conclusion, knockdown of NT5DC2 suppressed cell viability and proliferation, induced cell cycle arrest and promoted apoptosis in DLBCL cells by regulating the p53 signaling pathway and these effects were reversed by upregulation of IGF2BP2.

Indexed as

5'-NucleotidaseLymphoma, Large B-Cell, DiffuseRNA-Binding ProteinsTumor Suppressor Protein p53ApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansSignal Transduction5'-NucleotidaseIGF2BP2 protein, humanNT5DC2 protein, humanRNA-Binding ProteinsTumor Suppressor Protein p535'‑nucleotidase domain‑containing 2diffuse large B‑cell lymphomainsulin‑like growth factor 2 mRNA‑binding protein 2p53

Identifiers

PMID35894142
PMCPMC9366151
OpenAlexW4288033420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.